drugset / Trial / NCT03005067

To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold

NCT03005067

Phase 2 Completed 171 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.

Timeline

Start
2016-12-29
Primary completion
2017-06-07
Completion
2017-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbomer 940 Small molecule 140 mg Intranasal

Indications